Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Completed

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.

Key facts

Study ID

NCT00819195

Run by

University of California, San Francisco

People needed

17

Starts

2008-12-01

Expected to finish

2012-09-01

Last updated by the study team

2013-10-08

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Relapsing-remitting (RR) MS patients (McDonald criteria)
• Ages 18-55
• Males and females
• EDSS score ≤5
• No prior treatment with Copaxone
• Prior treatment with corticosteroids or interferon-beta (-1a or -1b) is acceptable, provided there is a washout period of at least one month

You may not qualify if…

• Treatment with Tysabri, Novantrone or cyclophosphamide
• Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate)
• Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis
• Pregnancy

Where it is running

• UCSF Multiple Sclerosis Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.